To bypass these contradictions, trials to treat diabetic cardiomyopathy or cardiac dysfunction (without diabetes) use empagliflozin, which is more SGLT2-selective as compared to canagliflozin and dapagliflozin, thus limiting the chances of SGLT1 channel cross-targeting [144,145,146]. The gene discussed is SLC5A2; the disease is diabetes mellitus.